A Retrospective Analysis of Endovascular Stent Insertion for Malignant Superior Vena Cava Obstruction, Focusing on Anticoagulation Practices
Current Oncology · 2025
DOI: 10.3390/curroncol32110601 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Joshua Walker und 4 weiteren Autor:innen. Beteiligte Einrichtung: Guy's and St Thomas' NHS Trust, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK. Hauptthemen laut MEDLINE: Anticoagulants, Stents, Superior Vena Cava Syndrome, Endovascular Procedures. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: A knowledge gap persists regarding anticoagulation therapy after endovascular stent insertion for malignant superior vena cava obstruction (mSVCO). Guidelines are supported by retrospective studies with a radiological focus and lack specific drug recommendations. No studies to date have captured the multi-disciplinary nature of decision-making over time.
Methods
This single-center retrospective service evaluation includes patients with solid organ malignancy who received a stent for mSVCO between July 2016 and May 2022. Patient and treatment characteristics, clinical outcomes and prescribing decisions were collected from medical records and analyzed.
Results
Of 49 patients (55% female, mean age 59), 73% had metastatic extra-thoracic disease at stent insertion. Technical success was achieved in 98% of cases and 92% survived to discharge. Forty-eight patients were followed until death. Median survival was 2.4 months. Post-procedure imaging (performed in 55% of patients) revealed 10 (21%) cases of systemic venous thromboembolism and 7 cases of stent thrombosis. Forty-four (91%) patients received anticoagulation therapy (62% therapeutic dose low molecular weight heparin). Those with thrombotic complications were fitter pre-procedurally than the rest of the cohort. There was one case of major bleeding. Twenty-two instances of therapy modification occurred following the initial plan, including nine changes due to a patient preference for oral therapy.
Conclusion
Patients undergoing stenting for mSVCO demonstrate high thrombotic risk and a poor prognosis. Anticoagulation plans are frequently modified post discharge due to changing risk profiles and patient preferences. Multi-disciplinary collaboration is essential to support patient-centered and individualized management. Future research should investigate direct oral anticoagulants and anti-platelet therapy and develop risk assessment tools for this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guy's and St Thomas' NHS Trust, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK.
- School of Cancer & Pharmaceutical Sciences, King's College London, Guy's Campus, Great Maze Pond, London SE1 1UL, UK.
ORCID-Profile: Joshua Walker, Athanasios Diamantopoulos, Spyridon Gennatas, Alexandros Georgiou
Zitieren
APA
Walker, J., Ravinthiranathan, A., Diamantopoulos, A., Gennatas, S., & Georgiou, A. (2025). A Retrospective Analysis of Endovascular Stent Insertion for Malignant Superior Vena Cava Obstruction, Focusing on Anticoagulation Practices. Current Oncology. https://doi.org/10.3390/curroncol32110601
Vancouver
Walker J, Ravinthiranathan A, Diamantopoulos A, Gennatas S, Georgiou A. A Retrospective Analysis of Endovascular Stent Insertion for Malignant Superior Vena Cava Obstruction, Focusing on Anticoagulation Practices. Current Oncology. 2025. doi:10.3390/curroncol32110601
BibTeX
@article{Walker2025,
author = {Walker, Joshua and Ravinthiranathan, Amsajini and Diamantopoulos, Athanasios and Gennatas, Spyridon and Georgiou, Alexandros},
title = {A Retrospective Analysis of Endovascular Stent Insertion for Malignant Superior Vena Cava Obstruction, Focusing on Anticoagulation Practices},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32110601}
}
EUVIMED